Reprint

New Trends in Diabetes, Hypertension and Cardiovascular Diseases

Edited by
March 2024
310 pages
  • ISBN978-3-7258-0537-2 (Hardback)
  • ISBN978-3-7258-0538-9 (PDF)

This is a Reprint of the Special Issue New Trends in Diabetes, Hypertension and Cardiovascular Diseases that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Cardiovascular disease (CVD) encompasses a range of disorders affecting the heart and blood vessels, including coronary heart disease, cerebrovascular disease, and conditions such as aortic aneurysm and lower extremity peripheral artery disease. It remains the leading cause of death worldwide, claiming 17.9 million lives annually, despite the availability of numerous therapeutic drugs. Thus, further research is warranted to enhance CVD treatment and reduce its morbidity and mortality.Diabetes and hypertension are conditions commonly found in aging populations that share common pathogenic pathways and are both strong, independent risk factors for CVD. Reducing blood glucose and blood pressure levels can significantly contribute to mitigating CVD-related morbidity and mortality.This Special Issue aims to present the latest perspectives and research findings on diabetes, hypertension, and CVD, comprising one Editorial article, eight review articles, and eight original research articles. These articles provide a comprehensive overview of recent developments in research on hypertension, insulin resistance/diabetes, and CVD, including atherosclerosis, aortic aneurysm, and myocardial infarction. They offer insights into CVD pathogenesis and facilitate the development of new therapeutic approaches.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
gut microbiome; atherosclerosis; TMAO; aging; gut dysbiosis; probiotics; short chain fatty acids; oxidative stress; obesity; cardiovascular disease; cardiometabolic diseases; coronary artery disease; metabolic syndrome; type 2 diabetes; sex; blood pressure; hypertension; GWAS; SNP; association; Inflammasome; atherosclerosis; NLRP3; IL-1β; IL-18; therapeutic target; NLRP3 inhibitors; ischemic stroke; hero; heat-resistant obscure; chaperones; SERPINE1 mRNA binding protein 1; SERBP1; SNP; activated partial thromboplastin time; body mass index; gene-environmental interaction; night shift; clock genes; circadian rhythm; blood pressure; ABPM; dipping; physician; internal medicine; T2D; diabetes; carbohydrate metabolism; insulin resistance; physiologic insulin resensitization (PIR); principle component analysis; hypertension; stress reactivity; age-related difference; ISIAH rat strain; myocardial infarction; human; inflammation; clinical outcomes; abdominal aortic aneurysm; thoracic aortic aneurysm; VSMC; phenotypic switching; redox signaling; oxidative stress; RAS; ACE inhibitors; ARBs; MARCKS; PKC; cathepsin; proteolysis; kidney; Duchenne Muscular Dystrophy; fibrosis; cardiac remodeling; cardiac dysfunction; tumor; macrophage recruitment; nitric oxide synthase; endothelial NOS; neuronal NOS; inducible NOS; NOS inhibitor; cardiovascular disease; vascular aging; genomic instability; mouse models; vessels-on-a-chip; abdominal aortic aneurysm; hydralazine; inflammation; atherosclerosis; n/a